By Brad Sorensen, CFA
OTCQB: INNMF
READ THE FULL INNMF RESEARCH REPORT
Amplia Therapeutics (OTCQB: INNMF) is a clinical-stage drug development company that has a compelling oncology story centered on a differentiated scientific approach and a focused clinical strategy targeting some of the most difficult-to-treat cancers, including pancreatic cancer and ovarian cancer. The company’s pipeline is built around its lead asset, narmafotinib (AMP945), a highly selective inhibitor of focal adhesion kinase (FAK), an enzyme that plays a critical role in tumor growth, metastasis, and the dense stromal environment that makes cancers such as pancreatic tumors particularly resistant to treatment. By inhibiting FAK, narmafotinib is designed to disrupt tumor cell signaling while also modifying the tumor microenvironment, potentially making cancers more responsive to chemotherapy and improving patient outcomes.
The company’s strategy is focused at the present time on two key studies, ACCENT and PRROSE, the first focused on advanced pancreatic cancer, and the second on ovarian cancer, both diseases with historically poor survival rates. The ACCENT trial represents the most encouraging near-term value driver. In this study, narmafotinib is combined with the chemotherapy combination of gemcitabine and nab-paclitaxel (Abraxane), a regimen widely viewed as more tolerable than other combinations. Data from the trial have demonstrated response rates and progression-free survival outcomes that compare favorably to historical benchmarks for chemotherapy alone, suggesting that the addition of a FAK inhibitor may enhance treatment efficacy without introducing significant additional toxicity (see below Figure). This balance of improved efficacy and manageable safety is particularly important in pancreatic cancer, where patient tolerability often limits treatment intensity, and positions narmafotinib as a potentially meaningful advancement in the standard of care if results continue to mature positively.
The PRROSE trial is investigating narmafotinib in combination with standard chemotherapy agents carboplatin and paclitaxel in women with high-grade serous ovarian cancer who have not responded adequately to initial platinum-based chemotherapy before surgery.
Beyond pancreatic and ovarian cancer, Amplia’s FAK inhibitor platform has broader potential applications in other fibrotic tumors and even non-oncology indications such as idiopathic pulmonary fibrosis, reflecting the central role of FAK signaling in both cancer progression and fibrotic disease and demonstrating the large potential upside Amplia has.
With an estimated 53,000 people expected to die from pancreatic cancer in 2026 in the US alone, the need for better and more effective treatments is urgent, and Amplia Therapeutics is giving hope to patients that the number of deaths may start to decrease. Doctors have described the process of finding a “cure” for pancreatic cancer as similar to attacking a large dam with pickaxes, with multiple pickaxes working on various parts of the wall. When the right pickaxes come together, the dam will break and a “cure” will be available—we believe that narmafotinib is one of those axes. With prospects like that, we believe INNMF is worth a look for investors with a longer time horizon and higher risk tolerance, with encouraging test results and solid management practices boding well for the future.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.